BRCA2 and leukemia: In contrast, recent studies have shown that in BRCA-proficient leukemia cells, inhibition of the TGFβ pathway promotes a reduction in ATM, BRCA1 and BRCA2 and a concomitant increase in olaparib sensitivity (55).